These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31476302)

  • 1. Chronic kidney disease: Biomarker diagnosis to therapeutic targets.
    Wang YN; Ma SX; Chen YY; Chen L; Liu BL; Liu QQ; Zhao YY
    Clin Chim Acta; 2019 Dec; 499():54-63. PubMed ID: 31476302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomic Signatures of Chronic Kidney Disease of Diverse Etiologies in the Rats and Humans.
    Zhang ZH; Chen H; Vaziri ND; Mao JR; Zhang L; Bai X; Zhao YY
    J Proteome Res; 2016 Oct; 15(10):3802-3812. PubMed ID: 27636000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR-based metabolomics associated with chronic kidney disease in humans and animals: a one health perspective.
    Hunter E; Percival B; Ahmad Z; Chang MW; Hunt JA; Tasker S; De Risio L; Wilson PB
    Mol Cell Biochem; 2021 Nov; 476(11):4133-4137. PubMed ID: 34312783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma biomarker discovery for early chronic kidney disease diagnosis based on chemometric approaches using LC-QTOF targeted metabolomics data.
    Benito S; Sánchez-Ortega A; Unceta N; Jansen JJ; Postma G; Andrade F; Aldámiz-Echevarria L; Buydens LMC; Goicolea MA; Barrio RJ
    J Pharm Biomed Anal; 2018 Feb; 149():46-56. PubMed ID: 29100030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomics in chronic kidney disease.
    Zhao YY
    Clin Chim Acta; 2013 Jun; 422():59-69. PubMed ID: 23570820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of obstructive nephropathy using a metabolomics approach in rat.
    Zhang ZH; He JQ; Qin WW; Zhao YY; Tan NH
    Chem Biol Interact; 2018 Dec; 296():229-239. PubMed ID: 30339777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Metabolomics study of metabolites associated with the glomerular filtration rate.
    Peng H; Liu X; Ieong CA; Tou T; Tsai T; Zhu H; Liu Z; Liu P
    BMC Nephrol; 2023 Apr; 24(1):105. PubMed ID: 37085754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabonomic biomarkers for risk factors of chronic kidney disease.
    Ye L; Mao W
    Int Urol Nephrol; 2016 Apr; 48(4):547-52. PubMed ID: 26897037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The link between phenotype and fatty acid metabolism in advanced chronic kidney disease.
    Chen DQ; Chen H; Chen L; Vaziri ND; Wang M; Li XR; Zhao YY
    Nephrol Dial Transplant; 2017 Jul; 32(7):1154-1166. PubMed ID: 28339984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biomarkers in Chronic Kidney Disease].
    Munguía-Miranda C; Paniagua-Sierra JR
    Rev Med Inst Mex Seguro Soc; 2017; 55(Suppl 2):S143-50. PubMed ID: 29697235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A metabolomics-based approach for predicting stages of chronic kidney disease.
    Kobayashi T; Yoshida T; Fujisawa T; Matsumura Y; Ozawa T; Yanai H; Iwasawa A; Kamachi T; Fujiwara K; Kohno M; Tanaka N
    Biochem Biophys Res Commun; 2014 Mar; 445(2):412-6. PubMed ID: 24530913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomics and renal disease.
    Rhee EP
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):371-9. PubMed ID: 26050125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis.
    Zhang ZH; Wei F; Vaziri ND; Cheng XL; Bai X; Lin RC; Zhao YY
    Sci Rep; 2015 Sep; 5():14472. PubMed ID: 26412413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplatform metabolomics provides insight into the molecular basis of chronic kidney disease.
    Kordalewska M; Macioszek S; Wawrzyniak R; Sikorska-Wiśniewska M; Śledziński T; Chmielewski M; Mika A; Markuszewski MJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jun; 1117():49-57. PubMed ID: 30999273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: Results from the Progredir Cohort.
    Titan SM; Venturini G; Padilha K; Goulart AC; Lotufo PA; Bensenor IJ; Krieger JE; Thadhani RI; Rhee EP; Pereira AC
    PLoS One; 2019; 14(3):e0213764. PubMed ID: 30883578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Untargeted metabolomics for plasma biomarker discovery for early chronic kidney disease diagnosis in pediatric patients using LC-QTOF-MS.
    Benito S; Sánchez-Ortega A; Unceta N; Andrade F; Aldámiz-Echevarria L; Goicolea MA; Barrio RJ
    Analyst; 2018 Sep; 143(18):4448-4458. PubMed ID: 30151522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer.
    Darshi M; Van Espen B; Sharma K
    Am J Nephrol; 2016; 44(2):92-103. PubMed ID: 27410520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Kidney Disease and the Search for New Biomarkers for Early Diagnosis.
    Saucedo AL; Perales-Quintana MM; Paniagua-Vega D; Sanchez-Martinez C; Cordero-Perez P; Minsky NW
    Curr Med Chem; 2018; 25(31):3719-3747. PubMed ID: 29521201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease.
    Cañadas-Garre M; Anderson K; McGoldrick J; Maxwell AP; McKnight AJ
    J Proteomics; 2019 Feb; 193():93-122. PubMed ID: 30292816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic biomarkers for chronic kidney disease.
    Breit M; Weinberger KM
    Arch Biochem Biophys; 2016 Jan; 589():62-80. PubMed ID: 26235490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.